Table 2.
| ECM gene of interest | EXP(↑) positive outcome | Dependent on other cellular components with prognostic evaluation | Cancer type |
|---|---|---|---|
| ADAMTS8 | N | +ADAMTS8, −ADAMTS15 | Breast |
| COL11A1 | N | AEBP1, COL11A1, COL5A1, COL6A2, LOX, POSTN, SNAI2, THBS2, TIMP3, VCAN | Ovarian |
| COL12A1 | Y | +ITGB1, +COL12A1 | Breast |
| COL12A1 | Y | TNKS1BP1, CPSF7, COL12A1 | Breast |
| COL12A1 | Drug resistance | COL1A1, COL5A2, COL12A1 and COL17A1 | Ovarian |
| COL15A1 | MUT = N | COL15A1, SRGAP1, SURF6, ABO | Ovarian |
| COL15A1 | Drug resistance | ITGB1BP3, COL3A1, COL5A2, COL15A1, TGFBI, DCN, LUM, MATN2, POSTN and EGFL6 | Ovarian |
| COL16A1 | Drug resistance | COL1A2, COL12A1, COL21A1, LOX, TGFBI, LAMB1, EFEMP1, GPC3, SDC2, MGP, MMP3, and TIMP3 | Ovarian |
| COL18A1 | N | COL4A2, COL6A2, COL6A3, COL18A1 | Liver |
| COL6A2 | N | AEBP1, COL11A1, COL5A1, COL6A2, LOX, POSTN, SNAI2, THBS2, TIMP3, VCANS | Ovarian |
| CTHRC1 | N | CTHRC1, Periostin | Ovarian |
| CTNNA1 | N | CD97, CTNNA1, DLC1, HAPLN2, LAMA4, LPP, MFAP4 | Breast |
| FN1 | N | FN, MMP7, MMP9, MMP11, TIMP1, TIMP2 | Breast |
| HAS1 | N | HYAL1, HAS1 | Bladder |
| HAS1 | Y | HAS1, HAS2 | Skin |
| LAMA1 | N | LAMA1, LAMA2, LAMA3B, LAMA4, LAMB1, LAMC3 | Breast |
| LAMA1 | MUT = N | LAMA1, LAMA3, LAMB1, LAMB4 | Gastric |
| LAMA2 | AB. METH = N | GABRA1, LAMA2 | Colon |
| LAMA3 | METH = N | LAMA3, LAMB3 | Bladder |
| LAMA3 | Y | LAMA3, LAMB3, LAMC2 | Prostate |
| MMP14 | N | FSCN1, MMP14 | Esophageal |
| MMP14 | N | MMP2, MMP14, MMP9, MAXND | Oral |
| MMP15 | N | MMP9, MMP15 | Breast |
| MMP15 | N | MMP15, MMP19 | Colon |
| MMP2 | Y | TIMP2, MMP | Colon |
| MMP7 | N | GDF15, MMP7 | Gastric |
| MMP9 | N | TIMP2, MMP | Colon |
| PECAM1 | N | TOP2A, GGH, PECAM1 | Gastric |
| SELP | N | SELP, AKT1 | Pancreatic |
| SPARC | Y | +NDRG1, -SPARC | Breast |
| SPG7 | N | NOTCH2, ITPRIP, FRMD6, GFRA4, OSBPL9, CPXCR1, SORCS2, PDC, C12ORF66, SLC38A9, OR10H5, TRIP13, MRPL52, DUSP21, BRCA1, ELTD1, SPG7, LASS6, DUOX2 | Colon |
| TIMP1 | N | LCN2, TIMP1 | Pancreatic |
| TIMP2 | N | TIMP2, MMP | Colon |
| TIMP2 | Y | TET1, TIMP2, TIMP3 | Prostate, Breast |
| TIMP3 | N | TSHR, RASSF1A, RARB2, DAPK, HMLH1, ATM, S100, P16, CTNNB1, GSTP1, CALCA, TIMP3, TGFßR2, THBS1, MINT1, CTNNB1, MT1G, PAK3, NISCH, DCC, AIM1, KIF1A. | Thyroid |
| VCAN | N | LCAN, VCAN | Colonb |
| Collagen type I | Drug resistance | MT1-MMP | Pancreatic |
| Collagen type IV | N | ELN-derived MMP12, COL4 | Breast |
| Collagen type IV | N | COL4, ELN-derived peptides | Breast |
a
Refer footnote from Table 1.
b
EXP(↑) Positive Outcome, positive expression of the ECM gene of interest correlates with a positive patient outcome; MUT, mutation; AB. METH, abnormal methylation; METH, methylation; ±, expression up/down required for predicted patient outcome.